NCT01492218View on ClinicalTrials.gov

Observational Study With Mixtard® 30 NovoLet® to Assess Patient Satisfaction

CompletedOBSERVATIONAL
Enrollment

1,330

Participants

Timeline

Start Date

March 15, 2004

Primary Completion Date

August 30, 2004

Study Completion Date

August 30, 2004

Conditions
DiabetesDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2
Interventions
DRUG

biphasic human insulin 30

Administered via the NovoLet® device and according to the instructions in the product insert or as instructed by the physician. Individually adjusted dosage as instructed by the physician.

Trial Locations (1)

1605

Novo Nordisk Investigational Site, Manila

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY

NCT01492218 - Observational Study With Mixtard® 30 NovoLet® to Assess Patient Satisfaction | Biotech Hunter | Biotech Hunter